AUB ScholarWorks

Zidovudine and interferon-α treatment induces a high response rate and reduces HTLV-1 proviral load and VEGF plasma levels in patients with adult T-cell leukemia from North East Iran

Show simple item record

dc.contributor.author Kchour G.
dc.contributor.author Makhoul N.
dc.contributor.author Mahmoudi M.
dc.contributor.author Kooshyar M.-M.
dc.contributor.author Shirdel A.
dc.contributor.author Rastin M.
dc.contributor.author Rafatpanah H.
dc.contributor.author Tarhini M.
dc.contributor.author Zalloua P.
dc.contributor.author Hermine Olivier
dc.contributor.author Farid R.
dc.contributor.author Bazarbachi A.
dc.contributor.editor
dc.date Feb-2007
dc.date.accessioned 2017-10-05T15:37:24Z
dc.date.available 2017-10-05T15:37:24Z
dc.date.issued 2007
dc.identifier 10.1080/10428190601071717
dc.identifier.isbn
dc.identifier.issn 10428194
dc.identifier.uri http://hdl.handle.net/10938/15680
dc.description.abstract Human T-cell lymphotropic virus type I (HTLV-I) associated adult T-cell leukemia-lymphoma (ATLL) is endemic in southern Japan, the Caribbean, intertropical Africa, and Brazil. Recently north east Iran, particularly the region of Mashhad, has been recognized as a new endemic region. ATLL is an aggressive T-cell lymphoproliferative disorder. Patients with ATLL have high plasma levels of VEGF that induce angiogenesis. Prognosis of ATLL remains poor because of immunosuppression and intrinsic resistance to chemotherapy. Important advances in the treatment of ATLL were reported with the combination of zidovudine (AZT) and interferon-α. We investigated the effect of AZT-IFN treatment on vascular endothelium growth factor (VEGF) plasma levels and HTLV-I proviral load in ATLL patients from the region of Mashhad. We confirmed that AZT-IFN treatment induces a high response rate and prolonged survival with minimal side effects. We also confirmed that VEGF plasma levels and HTLV-I proviral load are higher in ATLL patients than in asymptomatic carriers. We finally showed that AZT-IFN treatment reduced both HTLV-I proviral load and importantly VEGF plasma levels, suggesting a potential antiangiogenic effect of this therapy. These results provide further evidence for the efficacy and the mechanism of action of AZT-IFN therapy for ATLL in a developing country.
dc.format.extent
dc.format.extent Pages: (330-336)
dc.language English
dc.publisher ABINGDON
dc.relation.ispartof Publication Name: Leukemia and Lymphoma; Publication Year: 2007; Volume: 48; no. 2; Pages: (330-336);
dc.relation.ispartofseries
dc.relation.uri
dc.source Scopus
dc.subject.other
dc.title Zidovudine and interferon-α treatment induces a high response rate and reduces HTLV-1 proviral load and VEGF plasma levels in patients with adult T-cell leukemia from North East Iran
dc.type Article
dc.contributor.affiliation Kchour, G., Immunology Research Centre, Bu-Ali Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran
dc.contributor.affiliation Makhoul, N., Department of Internal Medicine, American University of Beirut, Beirut, Lebanon
dc.contributor.affiliation Mahmoudi, M., Immunology Research Centre, Bu-Ali Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran
dc.contributor.affiliation Kooshyar, M.-M., Department of Internal Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
dc.contributor.affiliation Shirdel, A., Department of Internal Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
dc.contributor.affiliation Rastin, M., Immunology Research Centre, Bu-Ali Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran
dc.contributor.affiliation Rafatpanah, H., Immunology Research Centre, Bu-Ali Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran
dc.contributor.affiliation Tarhini, M., Immunology Research Centre, Bu-Ali Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran
dc.contributor.affiliation Zalloua, P., Department of Internal Medicine, American University of Beirut, Beirut, Lebanon
dc.contributor.affiliation Hermine, Olivier, CNRS UMR 8603, Necker Hospital, Paris, France, Department of Hematology, Necker Hospital, Paris, France
dc.contributor.affiliation Farid, R., Immunology Research Centre, Bu-Ali Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran
dc.contributor.affiliation Bazarbachi, A., Department of Internal Medicine, American University of Beirut, Beirut, Lebanon
dc.contributor.authorAddress Bazarbachi, A.; Department of Internal Medicine, American University of Beirut, Beirut, Lebanon
dc.contributor.authorCorporate University: American University of Beirut Medical Center; Faculty: Faculty of Medicine; Department: Internal Medicine;
dc.contributor.authorDepartment Internal Medicine
dc.contributor.authorDivision
dc.contributor.authorEmail bazarbac@aub.edu.lb
dc.contributor.authorFaculty Faculty of Medicine
dc.contributor.authorInitials Kchour, G
dc.contributor.authorInitials Makhou, NJ
dc.contributor.authorInitials Mahmoudi, M
dc.contributor.authorInitials Kooshyar, MM
dc.contributor.authorInitials Shirdel, A
dc.contributor.authorInitials Rastin, M
dc.contributor.authorInitials Rafatpanah, H
dc.contributor.authorInitials Tarhini, M
dc.contributor.authorInitials Zalloua, PA
dc.contributor.authorInitials Hermine, O
dc.contributor.authorInitials Farid, R
dc.contributor.authorInitials Bazarbachi, A
dc.contributor.authorOrcidID Kooshyar, Mohammad -0000-0002-5355-3376
dc.contributor.authorReprintAddress Bazarbachi, A (reprint author), Amer Univ Beirut, Dept Internal Med, POB 113-6044, Beirut, Lebanon.
dc.contributor.authorResearcherID Kooshyar, Mohammad -H-9616-2013
dc.contributor.authorUniversity American University of Beirut Medical Center
dc.description.cited Abbaszadegan MR, 2003, J CLIN MICROBIOL, V41, P2593, DOI 10.1128-JCM.41.6.2593-2595.2003; Bazarbachi A, 2004, CANCER RES, V64, P2039, DOI 10.1158-0008-5472.CAN-03-2390; Bazarbachi A, 2000, LEUKEMIA, V14, P716, DOI 10.1038-sj.leu.2401742; Bazarbachi A, 2004, LANCET ONCOL, V5, P664, DOI 10.1016-S1470-2045(04)01608-0; Bazarbachi A, 1996, J ACQ IMMUN DEF SYND, V13, pS186, DOI 10.1097-00042560-199600001-00028; Datta A, 2006, BLOOD, V108, P1021, DOI 10.1182-blood-2006-01-0067; El-Sabban ME, 2002, BLOOD, V99, P3383, DOI 10.1182-blood.V99.9.3383; Feng X, 2003, J VIROL, V77, P13389, DOI 10.1128-JVI.77.24.13389-13395.2003; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053-sonc.2002.37263; Gessain A., 1996, HUMAN T CELL LYMPHOT, P33; GESSAIN A, 1985, LANCET, V2, P407; GILL PS, 1995, NEW ENGL J MED, V332, P1744, DOI 10.1056-NEJM199506293322603; Hayashibara T, 2001, CLIN CANCER RES, V7, P2719; HERMINE O, 1995, NEW ENGL J MED, V332, P1749, DOI 10.1056-NEJM199506293322604; Hermine Olivier, 2002, Hematol J, V3, P276, DOI 10.1038-sj.thj.6200195; HINUMA Y, 1982, INT J CANCER, V29, P631, DOI 10.1002-ijc.2910290606; ISONO T, 1990, LEUKEMIA RES, V14, P841, DOI 10.1016-0145-2126(90)90172-6; Kamihira S, 2003, CLIN LAB HAEMATOL, V25, P111, DOI 10.1046-j.1365-2257.2003.00503.x; KAPLAN JE, 1993, REV MED VIROL, V3, P137, DOI 10.1002-rmv.1980030304; Macchi B, 1997, J GEN VIROL, V78, P1007; Machuca A, 2000, J ACQ IMMUN DEF SYND, V24, P189; OGUMA S, 1992, CANCER RES, V52, P2620; Okayama A, 2004, INT J CANCER, V110, P621, DOI 10.1002-ijc.20144; Safai BJ, 1996, AIDS RES HUM RETROV, V12, P1185, DOI 10.1089-aid.1996.12.1185; SHIMOYAMA M, 1992, GANN MONOGRAPH CANCE, V39, P43; SHIMOYAMA M, 1991, BRIT J HAEMATOL, V79, P428, DOI 10.1111-j.1365-2141.1991.tb08051.x; Takatsuki F, 1990, RETROVIRUS BIOL HUMA, P147; Taylor GP, 1999, J VIROL, V73, P10289; Yamada Y, 2001, BRIT J HAEMATOL, V113, P375, DOI 10.1046-j.1365-2141.2001.02737.x
dc.description.citedCount 21
dc.description.citedTotWOSCount 19
dc.description.citedWOSCount 18
dc.format.extentCount 7
dc.identifier.articleNo
dc.identifier.coden LELYE
dc.identifier.pubmedID 17325893
dc.identifier.scopusID 34247892540
dc.identifier.url
dc.publisher.address 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
dc.relation.ispartofConference
dc.relation.ispartofConferenceCode
dc.relation.ispartofConferenceDate
dc.relation.ispartofConferenceHosting
dc.relation.ispartofConferenceLoc
dc.relation.ispartofConferenceSponsor
dc.relation.ispartofConferenceTitle
dc.relation.ispartofFundingAgency
dc.relation.ispartOfISOAbbr Leuk. Lymphoma
dc.relation.ispartOfIssue 2
dc.relation.ispartOfPart
dc.relation.ispartofPubTitle Leukemia and Lymphoma
dc.relation.ispartofPubTitleAbbr Leuk. Lymphoma
dc.relation.ispartOfSpecialIssue
dc.relation.ispartOfSuppl
dc.relation.ispartOfVolume 48
dc.source.ID WOS:000244528300019
dc.type.publication Journal
dc.subject.otherAuthKeyword
dc.subject.otherChemCAS cyclophosphamide, 50-18-0
dc.subject.otherChemCAS doxorubicin, 23214-92-8, 25316-40-9
dc.subject.otherChemCAS prednisone, 53-03-2
dc.subject.otherChemCAS vasculotropin, 127464-60-2
dc.subject.otherChemCAS vincristine, 57-22-7
dc.subject.otherChemCAS zidovudine, 30516-87-1
dc.subject.otherChemCAS vasculotropin A, 489395-96-2
dc.subject.otherChemCAS Antiviral Agents
dc.subject.otherChemCAS Interferon-alpha
dc.subject.otherChemCAS VEGFA protein, human
dc.subject.otherChemCAS Vascular Endothelial Growth Factor A
dc.subject.otherChemCAS Zidovudine, 30516-87-1
dc.subject.otherIndex alpha interferon
dc.subject.otherIndex cyclophosphamide
dc.subject.otherIndex doxorubicin
dc.subject.otherIndex prednisone
dc.subject.otherIndex vasculotropin
dc.subject.otherIndex vincristine
dc.subject.otherIndex zidovudine
dc.subject.otherIndex alpha interferon
dc.subject.otherIndex antivirus agent
dc.subject.otherIndex unclassified drug
dc.subject.otherIndex vasculotropin A
dc.subject.otherIndex VEGFA protein, human
dc.subject.otherIndex zidovudine
dc.subject.otherIndex adult
dc.subject.otherIndex aged
dc.subject.otherIndex antiangiogenic activity
dc.subject.otherIndex article
dc.subject.otherIndex cancer survival
dc.subject.otherIndex clinical article
dc.subject.otherIndex controlled study
dc.subject.otherIndex drug efficacy
dc.subject.otherIndex drug fever
dc.subject.otherIndex drug response
dc.subject.otherIndex dyspepsia
dc.subject.otherIndex edema
dc.subject.otherIndex female
dc.subject.otherIndex human
dc.subject.otherIndex Human T cell leukemia virus 1
dc.subject.otherIndex Iran
dc.subject.otherIndex male
dc.subject.otherIndex priority journal
dc.subject.otherIndex protein blood level
dc.subject.otherIndex side effect
dc.subject.otherIndex survival time
dc.subject.otherIndex T cell leukemia
dc.subject.otherIndex virus carrier
dc.subject.otherIndex virus load
dc.subject.otherIndex weight reduction
dc.subject.otherIndex blood
dc.subject.otherIndex drug combination
dc.subject.otherIndex drug effect
dc.subject.otherIndex Human T cell leukemia virus 1
dc.subject.otherIndex Human T cell leukemia virus infection
dc.subject.otherIndex Iran
dc.subject.otherIndex isolation and purification
dc.subject.otherIndex middle aged
dc.subject.otherIndex provirus
dc.subject.otherIndex T cell lymphoma
dc.subject.otherIndex treatment outcome
dc.subject.otherIndex virology
dc.subject.otherIndex Adult
dc.subject.otherIndex Antiviral Agents
dc.subject.otherIndex Drug Therapy, Combination
dc.subject.otherIndex Female
dc.subject.otherIndex HTLV-I Infections
dc.subject.otherIndex Human T-lymphotropic virus 1
dc.subject.otherIndex Humans
dc.subject.otherIndex Interferon-alpha
dc.subject.otherIndex Iran
dc.subject.otherIndex Leukemia-Lymphoma, T-Cell, Acute, HTLV-I-Associated
dc.subject.otherIndex Male
dc.subject.otherIndex Middle Aged
dc.subject.otherIndex Proviruses
dc.subject.otherIndex Treatment Outcome
dc.subject.otherIndex Vascular Endothelial Growth Factor A
dc.subject.otherIndex Viral Load
dc.subject.otherIndex Zidovudine
dc.subject.otherKeywordPlus VIRUS TYPE-I
dc.subject.otherKeywordPlus BLOOD-DONORS
dc.subject.otherKeywordPlus LYMPHOMA
dc.subject.otherKeywordPlus LEUKEMIA-LYMPHOMA
dc.subject.otherKeywordPlus ANGIOGENESIS
dc.subject.otherKeywordPlus COMBINATION
dc.subject.otherKeywordPlus TYPE-1
dc.subject.otherKeywordPlus PREVALENCE
dc.subject.otherKeywordPlus ANTIBODIES
dc.subject.otherKeywordPlus GROWTH
dc.subject.otherWOS Oncology
dc.subject.otherWOS Hematology


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search AUB ScholarWorks


Browse

My Account